167 related articles for article (PubMed ID: 29547736)
41. Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.
Wang X; Praça MSL; Wendel JRH; Emerson RE; DeMayo FJ; Lydon JP; Hawkins SM
Am J Pathol; 2021 Jul; 191(7):1281-1291. PubMed ID: 33882289
[TBL] [Abstract][Full Text] [Related]
42. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
[TBL] [Abstract][Full Text] [Related]
43. Novel TRERF1 mutations in Chinese patients with ovarian endometriosis.
Cao B; Zeng Y; Wu F; Liu J; Shuang Z; Xu X; Guo J
Mol Med Rep; 2018 Apr; 17(4):5435-5439. PubMed ID: 29393434
[TBL] [Abstract][Full Text] [Related]
44. Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis.
Teasley HE; Beesley A; Kim TH; Risinger J; Young SL; Jeong JW; Schammel DP; Lessey BA; Elder JW; Puls L
Reprod Sci; 2020 Jan; 27(1):145-151. PubMed ID: 32046380
[TBL] [Abstract][Full Text] [Related]
45. Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers
Khalique S; Nash S; Natrajan R
J Pathol; 2022 Sep; 258(1):1-3. PubMed ID: 35647895
[TBL] [Abstract][Full Text] [Related]
46. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
Trietsch MD; Spaans VM; ter Haar NT; Osse EM; Peters AA; Gaarenstroom KN; Fleuren GJ
Gynecol Oncol; 2014 Oct; 135(1):149-55. PubMed ID: 25072932
[TBL] [Abstract][Full Text] [Related]
47. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
48. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
49. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
50. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
Mao C; Zhou J; Yang Z; Huang Y; Wu X; Shen H; Tang J; Chen Q
PLoS One; 2012; 7(5):e36653. PubMed ID: 22586484
[TBL] [Abstract][Full Text] [Related]
51. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
Chakrabarty S; Varghese VK; Sahu P; Jayaram P; Shivakumar BM; Pai CG; Satyamoorthy K
Br J Cancer; 2017 Jun; 117(1):136-143. PubMed ID: 28524162
[TBL] [Abstract][Full Text] [Related]
52. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
Guan B; Rahmanto YS; Wu RC; Wang Y; Wang Z; Wang TL; Shih IeM
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24899687
[TBL] [Abstract][Full Text] [Related]
53. Biological significance of KRAS mutant allele expression in ovarian endometriosis.
Yachida N; Yoshihara K; Suda K; Nakaoka H; Ueda H; Sugino K; Yamaguchi M; Mori Y; Yamawaki K; Tamura R; Ishiguro T; Kase H; Motoyama T; Enomoto T
Cancer Sci; 2021 May; 112(5):2020-2032. PubMed ID: 33675098
[TBL] [Abstract][Full Text] [Related]
54. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
55. Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.
Sasamori H; Nakayama K; Razia S; Yamashita H; Ishibashi T; Ishikawa M; Sato S; Nakayama S; Otsuki Y; Fujiwaki R; Ishikawa N; Kyo S
Curr Oncol; 2022 May; 29(5):3658-3667. PubMed ID: 35621684
[TBL] [Abstract][Full Text] [Related]
56. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
57. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
58. Adenomyosis pathogenesis: insights from next-generation sequencing.
Bulun SE; Yildiz S; Adli M; Wei JJ
Hum Reprod Update; 2021 Oct; 27(6):1086-1097. PubMed ID: 34131719
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
60. Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology.
Guo SW
Hum Reprod Update; 2020 Apr; 26(3):423-449. PubMed ID: 32154564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]